Johnson & Johnson (NYSE:JNJ) Shares Bought by Consolidated Planning Corp

Posted by on Aug 9th, 2023

Consolidated Planning Corp lifted its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 31.3% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 25,091 shares of the company’s stock after buying an additional 5,976 shares during the period. Consolidated Planning Corp’s holdings in Johnson & Johnson were worth $3,889,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently added to or reduced their stakes in the business. GW&K Investment Management LLC purchased a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $35,000. Dark Forest Capital Management LP lifted its stake in Johnson & Johnson by 1,044.4% during the fourth quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock worth $36,000 after purchasing an additional 188 shares in the last quarter. Ruedi Wealth Management Inc. acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at $42,000. Kepos Capital LP purchased a new stake in shares of Johnson & Johnson in the 4th quarter valued at $45,000. Finally, VitalStone Financial LLC acquired a new position in Johnson & Johnson during the 4th quarter worth about $52,000. 67.57% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $173.15 on Wednesday. The company’s 50 day simple moving average is $163.47 and its 200-day simple moving average is $161.02. The firm has a market cap of $450.01 billion, a PE ratio of 35.05, a price-to-earnings-growth ratio of 2.90 and a beta of 0.54. Johnson & Johnson has a 12-month low of $150.11 and a 12-month high of $181.04. The company has a current ratio of 1.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.44.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings data on Thursday, July 20th. The company reported $2.80 EPS for the quarter, beating analysts’ consensus estimates of $2.62 by $0.18. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. The company had revenue of $25.53 billion for the quarter, compared to analyst estimates of $24.63 billion. During the same period in the previous year, the business posted $2.59 earnings per share. Johnson & Johnson’s quarterly revenue was up 6.3% on a year-over-year basis. As a group, equities analysts predict that Johnson & Johnson will post 10.75 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 7th. Stockholders of record on Monday, August 28th will be paid a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a dividend yield of 2.75%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 96.36%.

Insider Activity at Johnson & Johnson

In other news, VP Peter Fasolo sold 20,000 shares of the firm’s stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the sale, the vice president now owns 102,696 shares in the company, valued at approximately $17,491,182.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, VP Peter Fasolo sold 20,000 shares of the stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the transaction, the vice president now owns 102,696 shares in the company, valued at approximately $17,491,182.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider William Hait sold 14,698 shares of the business’s stock in a transaction dated Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the sale, the insider now directly owns 87,747 shares in the company, valued at approximately $15,092,484. The disclosure for this sale can be found here. Insiders have sold a total of 47,163 shares of company stock worth $7,928,856 in the last three months. Insiders own 0.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on JNJ shares. JPMorgan Chase & Co. boosted their price target on shares of Johnson & Johnson from $175.00 to $180.00 and gave the stock a “neutral” rating in a research note on Friday, July 21st. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a report on Monday, July 31st. StockNews.com initiated coverage on shares of Johnson & Johnson in a research note on Thursday, May 18th. They issued a “strong-buy” rating for the company. Citigroup assumed coverage on Johnson & Johnson in a research note on Tuesday, May 30th. They issued a “buy” rating and a $185.00 price objective on the stock. Finally, Atlantic Securities boosted their target price on Johnson & Johnson from $167.00 to $170.00 and gave the stock a “neutral” rating in a research note on Friday, August 4th. Eight analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $171.80.

Check Out Our Latest Stock Analysis on JNJ

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.